Literature DB >> 12115162

Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the cognitive symptoms inventory.

Graciela S Alarcón1, Leanne Cianfrini, Laurence A Bradley, Martha L Sanchez, Kemi Brooks, Alan W Friedman, Bruce A Baethge, Barri J Fessler, Holly M Bastian, Jeffrey M Roseman, Gerald McGwin, John D Reveille.   

Abstract

OBJECTIVE: To determine the factor structure of the Cognitive Symptoms Inventory (CSI) in patients with systemic lupus erythematosus (SLE) participating in a multiethnic longitudinal study of outcome, the Lupus in Minority populations, Nature versus nurture (LUMINA) study.
METHODS: LUMINA patients of Hispanic (n = 48), African American (n = 64), and Caucasian (n = 44) ethnicity who had a study visit (enrollment or followup) between January 1 and September 30, 2000 were included. Patients completed the CSI, a 21-item self-report measure of cognitive function. Sociodemographic, clinical, immunologic, psychosocial, and behavioral variables were ascertained per protocol and as previously described. Data were analyzed with SPSS. The factor structure of the CSI was determined using the principal axis method with oblique rotation as decided by Gorsuch. All factors having an Eigenvalue greater than 1 were considered. A 4-factor solution was derived that accounted for 42.6% of the common variance. The correlations between patient factor scale scores and variables from the demographic, clinical, psychosocial, and behavioral domains were then examined.
RESULTS: The four factors and their respective variance are, Attention/Concentration (28.8%), Pattern Recognition/Activity Management (5.7%), Intermediate Memory (4.7%), and Initiation of Executive Functions (3.4%); each factor correlated with the total CSI score. Overall, patients' factor scale scores were positively and significantly correlated with other measures of cognitive dysfunction such as the Systemic Lupus Activity Measure (neuromotor domain) or the Systemic Lupus International Collaborating Clinics Damage Index (neurocognitive impairment), as well as with measures of fatigue, maladaptive coping skills, poor mental functioning, poor social support, and helplessness. They were, however, not correlated with sociodemographic or clinical variables.
CONCLUSIONS: In addition to demonstrating that the CSI can be used to measure cognitive impairment in patients with SLE in the research setting, we have determined a 4-factor solution for the CSI that appears to have adequate metric properties. At present, the CSI may best be used as a screen for difficulties in daily activities involving intermediate memory, concentration, attention, and executive function. Nevertheless, further work with the CSI items and factor scales is necessary to establish internal and test-retest reliability of the factor scales; and provide additional evidence of the convergent and predictive validity of these scales in larger samples of patients from each ethnic subgroup.

Entities:  

Mesh:

Year:  2002        PMID: 12115162     DOI: 10.1002/art.10457

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment.

Authors:  Melanie J Harrison; Lisa D Ravdin
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 2.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 3.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

4.  Impact of memory impairment on employment status in persons with systemic lupus erythematosus.

Authors:  Pantelis Panopalis; Laura Julian; Jinoos Yazdany; Joann Zell Gillis; Laura Trupin; Aimee Hersh; Lindsey A Criswell; Patricia Katz; Edward Yelin
Journal:  Arthritis Rheum       Date:  2007-12-15

Review 5.  Cognitive Dysfunction in Systemic Lupus Erythematosus: Immunopathology, Clinical Manifestations, Neuroimaging and Management.

Authors:  Dominic Seet; Nur Azizah Allameen; Jiacai Cho; Anselm Mak; Sen Hee Tay
Journal:  Rheumatol Ther       Date:  2021-05-15

6.  Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage.

Authors:  Fabrizio Conti; Cristiano Alessandri; Carlo Perricone; Rossana Scrivo; Soheila Rezai; Fulvia Ceccarelli; Francesca Romana Spinelli; Elena Ortona; Massimo Marianetti; Concetta Mina; Guido Valesini
Journal:  PLoS One       Date:  2012-03-26       Impact factor: 3.240

7.  CD8+DR+ T-Cells and C3 Complement Serum Concentration as Potential Biomarkers in Thrombotic Antiphospholipid Syndrome.

Authors:  Elizabeth Sarmiento; Jonathan Dale; Mauricio Arraya; Antonio Gallego; Nallibe Lanio; Joaquin Navarro; Javier Carbone
Journal:  Autoimmune Dis       Date:  2014-05-29

8.  Pragmatic language dysfunction in systemic lupus erythematosus patients: Results from a single center Italian study.

Authors:  Fulvia Ceccarelli; Carmelo Pirone; Concetta Mina; Alfredo Mascolo; Carlo Perricone; Laura Massaro; Francesca Romana Spinelli; Cristiano Alessandri; Guido Valesini; Fabrizio Conti
Journal:  PLoS One       Date:  2019-11-04       Impact factor: 3.240

9.  The Montreal Cognitive Assessment Test: A Useful Tool in Screening of Cognitive Impairment in Patients With Systemic Lupus Erythematosus.

Authors:  Nicolas Paez-Venegas; Bethel Jordan-Estrada; Efrain Chavarria-Avila; Felipe Perez-Vazquez; Eduardo Gómez-Bañuelos; Rafael Medina-Dávalos; José-Ángel Ontiveros-González; Gustavo-Ignacio Diaz-Rubio; Rosa E Navarro-Hernandez; Mónica Vázquez-Del Mercado
Journal:  J Clin Rheumatol       Date:  2019-12       Impact factor: 3.517

10.  Cognitive dysfunction among people with systemic lupus erythematosus is associated with reduced participation in daily life.

Authors:  Moon Young Kim; Deepali Sen; Ronald R Drummond; Matthew C Brandenburg; Kathryn Lp Biesanz; Alfred Hj Kim; Seth A Eisen; Carolyn M Baum; Erin R Foster
Journal:  Lupus       Date:  2021-04-01       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.